Papain (papaya proteinase I) is a sulfhydryl protease from the latex of the papaya fruit. Papain breaks down intercellular matrix of cartilage.

Papaya Extract is extracted from Carica papaya, which has anticancer activities.

Papaya Leaf Extract is extracted from the leaves of Carica papaya, which has anticancer, anti-inflammatory, antidiabetic, and antiviral activities.

Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM.

Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.

Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.

Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.

Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.

Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.

Parsaclisib (INCB050465, INCB-50465, IBI376) is a potent and highly selective PI3Kδ(PI3K delta) inhibitor with an IC50 of 1 nM at 1 mM ATP in biochemical assay and approximately 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ; and 57 other kinases.

Parsaclisib (INCB050465, INCB-50465, IBI376) is a potent and highly selective PI3Kδ(PI3K delta) inhibitor with an IC50 of 1 nM at 1 mM ATP in biochemical assay and approximately 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ; and 57 other kinases.

Parsatuzumab (Anti-EGFL7) is a humanized monoclonal antibody targeting EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition. MW: 145.5 KD.

Parsatuzumab (Anti-EGFL7) is a humanized monoclonal antibody targeting EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition. MW: 145.5 KD.

Parsatuzumab (Anti-EGFL7) is a humanized monoclonal antibody targeting EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition. MW: 145.5 KD.

Parsley Extract is extracted from Petroselinum crispum, which has pharmacological activity including antioxidant, hepatoprotective, brain protective, anti-diabetic, analgesic, spasmolytic, and immunosuppressant.

Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD.

Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD.

Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD.

Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue with high binding affinity for somatostatin receptor (SSTR) subtypes sst1,2,3 and sst5. It potently suppresses GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing’s disease.

Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue with high binding affinity for somatostatin receptor (SSTR) subtypes sst1,2,3 and sst5. It potently suppresses GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing’s disease.

Passiflora caerulea Linnaeus Extract is drawed from Passiflora caerulea L., which contains higher amounts of the monoamine oxidase (MAO)-inhibitor harmine compared to Passiflora incarnate.

Passion Fruit Extract is extracted from Passiflora edulis Sims.

Pateclizumab (Anti-TNFSF1 / TNFb) is a humanized monoclonal antibody that blocks and depletes anti-lymphotoxin α (LTα). It has a great potential for the treatment of rheumatoid arthritis (RA). MW : 145.5 KD.

Pateclizumab (Anti-TNFSF1 / TNFb) is a humanized monoclonal antibody that blocks and depletes anti-lymphotoxin α (LTα). It has a great potential for the treatment of rheumatoid arthritis (RA). MW : 145.5 KD.

Pateclizumab (Anti-TNFSF1 / TNFb) is a humanized monoclonal antibody that blocks and depletes anti-lymphotoxin α (LTα). It has a great potential for the treatment of rheumatoid arthritis (RA). MW : 145.5 KD.

Patriniae Extract is extracted from Patrinia scabiosaefolia or Patrinia villosa, is able to significantly reduce the biofilm formation and dramatically alters the structure of the mature biofilms of Pseudomonas aeruginosa.

Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.

Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.